HIF1A and breast cancer: To target the pathway of hypoxia, the HIF‐1α inhibitor px‐478 (20 μm) was used to treat breast cancer cells, which inhibited the cell number of SKBR‐3 cells but not luminal subtype cell lines (Figure 7M).